Nachrichten zur Intellia Therapeutics Aktie

Cathie Wood’s ARK sells Shopify stock, buys Intellia Therapeutics

Cathie Wood’s ARK sells Shopify stock, buys Intellia Therapeutics…

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

Intellias CRISPR pipeline and Omeross newly approved therapy each bring unique risk and reward profiles, see how their financials and…

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?

Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

Intellia Therapeutics (NTLA) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?

NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in…

Cathie Wood Buys Tumbling Robinhood Stock, ARK Adds $30 Mil Of This Stock

Cathie Woods ARK Invest bought Robinhood stock as shares fell, loads up on Kratos Defense, Intellia Therapeutics. Firm sells bitcoin…

Intellia Therapeutics prices $180M stock offering at discount

…

Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema Transcript

…

Intellia Therapeutics (NTLA) – CRISPR-Pionier vor historischem Durchbruch: Aktie explodiert vor entscheidenden Phase-3-Daten!

Die Aktie von Intellia Therapeutics sorgt für Aufsehen an den Märkten und springt im Vorfeld eines potenziell bahnbrechenden Studiendaten-Updates…

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone…

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused…

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing…

Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate

…

Intellia Therapeutics: Aufsichtsrat nutzt den Kurseinbruch für einen 1,4 Mio. USD schweren Aktienkauf

Intellia Therapeutics (NTLA) positioniert sich im Bereich der CRISPR/Cas9-Technologie, um Krankheiten direkt an ihrem genetischen Ursprung zu heilen. Das Unternehmen…

Cathie Wood shells out $1.3 million on biotech stock

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics…

Intellia (NTLA) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool.DATEFriday, November 7, 2025 at 5:46 a.m. ETCALL PARTICIPANTSPresident and Chief Executive Officer — John LeonardChief…

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

CAMBRIDGE, Mass., Nov. 08, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing…

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

…

Intellia Therapeutics (NTLA) - CRISPR-Spezialist überzeugt mit starker Pipeline!

Geschäftstreiber: Intellia Therapeutics (NTLA) hat sich auf die Behandlung von genetischen Krankheiten spezialisiert und setzt dabei vor allem auf die…

Intellia Therapeutics (NTLA) Upgraded to Buy: Heres What You Should Know

Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings prospects.…

Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Heres What You Should Know

The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this…

Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?

Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this…

Intellia Therapeutics stock hits 52-week high at 21.49 USD By Investing.com

Intellia Therapeutics stock hits 52-week high at 21.49 USD…

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting…

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

…

Intellia Therapeutics: Wells Fargo sieht 173 % Kurspotenzial!

Intellia Therapeutics (NTLA) hat es auf die Liste der Top-10 Kursziele der Analysten geschafft. Der Biotech hat bereits in den…

Citizens JMP reiterates Market Perform rating on Intellia Therapeutics stock By Investing.com

Citizens JMP reiterates Market Perform rating on Intellia Therapeutics stock…

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

…

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Editas Medicine Is Great. Heres Why You Shouldnt Buy It.

The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led…

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

CAMBRIDGE, Mass., May 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company…

Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?

The mean of analysts price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this…

Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline

Intellia Therapeutics (NTLA) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

NTLA DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – NTLA

NEW YORK, April 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and ICON and Encourages Investors to Contact the Firm

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Alarum, and Merck and Encourages Investors to Contact the Firm

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

NEW YORK, March 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To…

Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)

…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and Merck and Encourages Investors to Contact the Firm

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the…

ROSEN, LEADING INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?

Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA

NEW YORK, Feb. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,…

INTELLIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Intellia Therapeutics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?

The mean of analysts price targets for Intellia Therapeutics (NTLA) points to a 422.4% upside in the stock. While this…

Intellia Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NTLA

Robbins LLP is Investigating Allegations that Intellia Therapeutics, Inc. (NTLA) Misled Investors Regarding the Viability of its Drug Candidate…